Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05979415 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes
A Phase 2 study, sponsored by Alexza Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT05979415 is a Phase 2 study that was terminated before completion, run by Alexza Pharmaceuticals. The registered enrollment target is 8 participants.
The verdict
NCT05979415, a Phase 2 study, was terminated before completion, sponsored by Alexza Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study will be conducted with In-clinic visits and treatment at home for each patient with established Parkinson's disease (PD) experiencing daily OFF episodes.
Interventions
- DRUG Apomorphine Cartridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2023-09-27 |
| Est. Completion | 2024-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05979415
The ClinicalTrials.gov registry entry for NCT05979415 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexza Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Apomorphine Cartridge is the first listed.
NCT05979415 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05979415 about?
NCT05979415 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes". This study will be conducted with In-clinic visits and treatment at home for each patient with established Parkinson's disease (PD) experiencing daily OFF episodes.
What is the current status of trial NCT05979415?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2023-09-27. Estimated completion is 2024-02-28.
What interventions are being tested in trial NCT05979415?
The interventions under investigation include: Apomorphine Cartridge (DRUG).
Who is sponsoring clinical trial NCT05979415?
This trial is sponsored by Alexza Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.